Bayer leads Metagenomi complete $65M series A financing round
US, Nov. 16 -- based Metagenomi, a next generation gene editing company launched by UC Berkeley scientists in 2018, successfully completed a $ 65 million Series A financing round and emerged from stealth mode. The Series A round was led by Leaps by Bayer and Humboldt Fund. Other investors included Sozo Ventures, Agent Capital, InCube Ventures and HOF Capital. CRISPR-based gene editing is one of the most important discoveries in recent years, and a critical technology for next generation therapeutic development. With the ability to edit DNA, scientists can address a whole range of diseases - but there are still hurdles to overcome such as delivery, immunogenicity, selectivity, and genomic accessibility with current technologies. To enable ...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.